Kiora Pharmaceuticals Inc. (KPRX)
$2.51
$-0.11
(-4.20%)
As on 31-Aug-2026 16:00EDT
Market cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
-1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.5
-
Face value
--
-
Shares outstanding
4,424,387
10 Years Aggregate
CFO
$-77.48 Mln
EBITDA
$-93.52 Mln
Net Profit
$-105.22 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kiora Pharmaceuticals (KPRX)
| 27.4 | -1.8 | -6.3 | -9.7 | -16.6 | -66.6 | -56.1 |
|
BSE Sensex*
| -9.1 | -1.4 | 3.0 | -3.5 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Kiora Pharmaceuticals (KPRX)
| -40.3 | -29.6 | -84.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kiora Pharmaceuticals (KPRX)
|
2.5 | 11.6 | 0.0 | -11.0 | -- | -66.6 | -- | 0.7 |
| 17.5 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 198.5 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.1 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 23.9 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.1 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 68.2 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 139.0 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small... molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. Read more
-
President, CEO & Director
Dr. Brian M. Strem Ph.D.
-
President, CEO & Director
Dr. Brian M. Strem Ph.D.
-
Headquarters
Encinitas, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kiora Pharmaceuticals (KPRX)
What is the current share price of Kiora Pharmaceuticals Inc (KPRX) Today?
The share price of Kiora Pharmaceuticals Inc (KPRX) is $2.51 (NASDAQ) as of 31-Aug-2026 16:00 EDT. Kiora Pharmaceuticals Inc (KPRX) has given a return of -16.61% in the last 3 years.
What is the current PB & PE ratio of Kiora Pharmaceuticals Inc (KPRX)?
Since, TTM earnings of Kiora Pharmaceuticals Inc (KPRX) is negative, P/E ratio is not available.
The P/B ratio of Kiora Pharmaceuticals Inc (KPRX) is 0.70 times as on 28-Aug-2026, a 91 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.75 |
0.50 |
2024 |
2.75 |
0.38 |
2023 |
-0.32 |
0.66 |
2022 |
-0.45 |
0.54 |
2021 |
-1.39 |
1.31 |
What is the 52 Week High and Low of Kiora Pharmaceuticals Inc (KPRX)?
The 52-week high and low of Kiora Pharmaceuticals Inc (KPRX) are Rs 2.95 and Rs 1.76 as of 01-Sep-2026.
What is the market cap of Kiora Pharmaceuticals Inc (KPRX)?
Kiora Pharmaceuticals Inc (KPRX) has a market capitalisation of $ 12 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kiora Pharmaceuticals Inc (KPRX)?
Before investing in Kiora Pharmaceuticals Inc (KPRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.